Back to search results

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

Abroad (travel likely)RecruitingPHASE3

Conditions

Sickle Cell Disease

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University Of Alabama, Birmingham, Alabama, United States

    Contact: Study coordinator (Jeanine Dumas) · jdumas@uabmc.edu · +1 205 638 9285
    Contact: Principal Investigator (Chibuzo Churchill Ilonze)

  • Ctr for Inherited Blood Disorders, Orange, California, United States

    Contact: Study coordinator (Emily Lopez) · elopez@cibd-ca.org
    Contact: Principal Investigator (Vanessa Salinas)

  • Childrens National Hospital, Washington D.C., District of Columbia, United States

    Contact: Study coordinator (Taylor Quinn) · tquinn@childrensnational.org · 202-476-5000
    Contact: Principal Investigator (Andrew Campbell)

  • University of Florida, Jacksonville, Florida, United States

    Contact: Study coordinator (Tatiana Elias-Grajeda) · tatiana.elias-grajeda@jax.ufl.edu
    Contact: Principal Investigator (Gabriela Bastidas)

  • Augusta University Georgia, Augusta, Georgia, United States

    Contact: Study coordinator (Latanya Bowman) · lbowman@augusta.edu · 706-721-2941
    Contact: Principal Investigator (Abdullah Kutlar)

  • WCG Sonar Clinical Research, Riverdale, Georgia, United States

    Contact: Study coordinator (Ify Anierobi) · ianierobi@sonarcr.com
    Contact: Principal Investigator (Anthony Onyegbula)

  • Norton Children s Hospital, Louisville, Kentucky, United States

    Contact: Study coordinator (Meagan Despain) · meagan.despain@louisville.edu
    Contact: Principal Investigator (Ashok Raj)

  • The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

    Contact: Study coordinator (Goodness Che) · anchang1@jhmi.edu · 410-955-2812
    Contact: Principal Investigator (Lydia Pecker)

  • Southern Specialty Research, Flowood, Mississippi, United States

    Contact: Study coordinator (Wendy Thomson) · wendy.thomson@southernspecialty.org
    Contact: Principal Investigator (Sharon Pennington)

  • Childrens Hospital at Montefiore, The Bronx, New York, United States

    Contact: Study coordinator (Karen Ireland) · kireland@montefiore.org · 718-741-2384
    Contact: Principal Investigator (Kaitlin Strumph)

  • East Carolina University, Greenville, North Carolina, United States

    Contact: Study coordinator (Tori Donadio) · donadiov21@ecu.edu
    Contact: Principal Investigator (Beng Fuh)

  • Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States

    Contact: Study coordinator (Julie Fountain) · julie.fountain@advocatehealth.org
    Contact: Principal Investigator (Alex George)

  • Spoknwrdclinicaltrials, Easton, Pennsylvania, United States

    Contact: Study coordinator (Anne Murunga) · amurunga@spoknwrdclinicaltrials.com
    Contact: Principal Investigator (Hayman Salib)

  • U of TX Health Science Ct, Houston, Texas, United States

    Contact: Study coordinator (Eyuel Baherey) · Eyuel.L.Baherey@uth.tmc.edu
    Contact: Principal Investigator (Modupe Idowu)

  • Novartis Investigative Site, Salvador, Estado de Bahia, Brazil

  • Novartis Investigative Site, São Luís, Maranhão, Brazil

  • Novartis Investigative Site, Campinas, São Paulo, Brazil

  • Novartis Investigative Site, Ribeirão Preto, São Paulo, Brazil

  • Novartis Investigative Site, Sao Jose Rio Preto, São Paulo, Brazil

  • Novartis Investigative Site, São Paulo, São Paulo, Brazil

  • Novartis Investigative Site, São Paulo, São Paulo, Brazil

  • Novartis Investigative Site, Medellín, Antioquia, Colombia

  • Novartis Investigative Site, Cali, Valle del Cauca Department, Colombia

  • Novartis Investigative Site, Cali, Valle del Cauca Department, Colombia

  • Novartis Investigative Site, Montería, Colombia

  • Novartis Investigative Site, Ahero, Kisumu County, Kenya

  • Novartis Investigative Site, Kisumu, Kenya

  • Novartis Investigative Site, Kisumu, Kenya

  • Novartis Investigative Site, Siaya, Kenya

  • Novartis Investigative Site, Kampala, Uganda

  • Novartis Investigative Site, Masaka, Uganda

  • Novartis Investigative Site, Tororo, Uganda

View source on ClinicalTrials.gov(opens in a new tab)